| Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis, G Adamis, ... Nature medicine 27 (10), 1752-1760, 2021 | 442 | 2021 |
| PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy G Papatheodoridis, G Dalekos, V Sypsa, C Yurdaydin, M Buti, J Goulis, ... Journal of hepatology 64 (4), 800-806, 2016 | 439 | 2016 |
| The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B GV Papatheodoridis, R Idilman, GN Dalekos, M Buti, H Chi, ... Hepatology 66 (5), 1444-1453, 2017 | 304 | 2017 |
| Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics NK Gatselis, K Zachou, GK Koukoulis, GN Dalekos World journal of gastroenterology: WJG 21 (1), 60, 2015 | 253 | 2015 |
| autoimmune hepatitis–current management and challenges K Zachou, P Muratori, GK Koukoulis, A Granito, N Gatselis, A Fabbri, ... Alimentary pharmacology & therapeutics 38 (8), 887-913, 2013 | 239 | 2013 |
| Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of … K Zachou, N Gatselis, G Papadamou, EI Rigopoulou, GN Dalekos Journal of hepatology 55 (3), 636-646, 2011 | 221 | 2011 |
| Adipokines as mediators of endothelial function and atherosclerosis G Ntaios, NK Gatselis, K Makaritsis, GN Dalekos Atherosclerosis 227 (2), 216-221, 2013 | 192 | 2013 |
| Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir GV Papatheodoridis, GN Dalekos, C Yurdaydin, M Buti, J Goulis, ... Journal of hepatology 62 (2), 363-370, 2015 | 179 | 2015 |
| Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview GN Dalekos, K Zachou, C Liaskos, N Gatselis European journal of internal medicine 13 (5), 293-303, 2002 | 163 | 2002 |
| An open label trial of anakinra to prevent respiratory failure in COVID-19 E Kyriazopoulou, P Panagopoulos, S Metallidis, GN Dalekos, G Poulakou, ... Elife 10, e66125, 2021 | 158 | 2021 |
| Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis E Kyriazopoulou, T Huet, G Cavalli, A Gori, M Kyprianou, P Pickkers, ... The Lancet Rheumatology 3 (10), e690-e697, 2021 | 142 | 2021 |
| Spontaneous spondylodiscitis: presentation, risk factors, diagnosis, management, and outcome E Kapsalaki, N Gatselis, A Stefos, K Makaritsis, A Vassiou, I Fezoulidis, ... International Journal of Infectious Diseases 13 (5), 564-569, 2009 | 115 | 2009 |
| A real‐world study focused on the long‐term efficacy of mycophenolate mofetil as first‐line treatment of autoimmune hepatitis K Zachou, NK Gatselis, P Arvaniti, S Gabeta, EI Rigopoulou, ... Alimentary pharmacology & therapeutics 43 (10), 1035-1047, 2016 | 112 | 2016 |
| Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population GV Papatheodoridis, V Sypsa, G Dalekos, C Yurdaydin, F van Boemmel, ... Journal of hepatology 68 (6), 1129-1136, 2018 | 110 | 2018 |
| Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase CFM Perez, MH Harms, KD Lindor, HR Van Buuren, GM Hirschfield, ... Official journal of the American College of Gastroenterology| ACG 115 (7 …, 2020 | 100 | 2020 |
| Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score? NK Gatselis, K Zachou, P Papamichalis, GK Koukoulis, S Gabeta, ... Digestive and liver disease 42 (11), 807-812, 2010 | 99 | 2010 |
| Anti‐cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2‐glycoprotein I cofactor or features of antiphospholipid syndrome K Zachou, C Liaskos, DK Christodoulou, M Kardasi, G Papadamou, ... European journal of clinical investigation 33 (2), 161-168, 2003 | 97 | 2003 |
| Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B GV Papatheodoridis, V Sypsa, GN Dalekos, C Yurdaydin, F Van Boemmel, ... Journal of hepatology 72 (6), 1088-1096, 2020 | 96 | 2020 |
| Clinical and virological heterogeneity of hepatitis delta in different regions world‐wide: the Hepatitis Delta International Network (HDIN) A Wranke, LM Pinheiro Borzacov, R Parana, C Lobato, S Hamid, ... Liver International 38 (5), 842-850, 2018 | 94 | 2018 |
| Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B GV Papatheodoridis, GN Dalekos, R Idilman, V Sypsa, F Van Boemmel, ... Journal of hepatology 73 (5), 1037-1045, 2020 | 84 | 2020 |
